LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky’s rating ...
Wedbush analyst David Nierengarten maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback